DAT-2645
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DAT-2645, covering 2024-09-27 to 2024-09-27. Get the full timeline:
Most recent: Clinical Trial Update: A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway [Phase 1]